Company Overview

Amphastar Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredients (APIs). The company operates primarily within the pharmaceutical and biotechnology industries, with a concentration on technically challenging drug products that often involve complex formulations, sterile manufacturing, or device-based delivery systems. Amphastar generates revenue through sales of generic pharmaceuticals, branded products, insulin APIs, and contract manufacturing activities.

The company’s primary business lines include injectable drugs used in hospital and emergency settings, intranasal products, inhalation therapies, and diabetes-related pharmaceutical ingredients. Key revenue drivers have included products such as glucagon emergency kits, naloxone products, enoxaparin, and Primatene MIST. Amphastar serves hospitals, retail pharmacies, wholesalers, group purchasing organizations, and government healthcare channels primarily in the United States, while also maintaining international commercial and manufacturing operations. The company traces its origins to 1996 and expanded through internal development, manufacturing integration, and acquisitions, including the purchase of BAQSIMI from Eli Lilly and Company in 2023, which broadened its branded diabetes emergency treatment portfolio.

Business Operations

Amphastar conducts operations through integrated pharmaceutical development and manufacturing activities centered around complex generic and proprietary products. The company’s operating structure includes pharmaceutical finished products, API manufacturing, and contract manufacturing services. Its core assets include sterile injectable manufacturing capabilities, analytical testing infrastructure, respiratory drug-device technologies, and insulin API production facilities. Amphastar manufactures products internally through subsidiaries including International Medication Systems, Ltd., Amphastar Nanjing Pharmaceuticals Inc., and BAQSIMI-related operations acquired from Eli Lilly. The company’s vertically integrated model supports formulation development, regulatory filing, manufacturing, and commercialization.

The company operates across both domestic and international markets, with major revenue concentration in the United States. Manufacturing and research operations span facilities in California, New York, China, and France. Amphastar also maintains partnerships and supply relationships related to pharmaceutical distribution and production. Revenue generation is driven by sales of generic injectables, branded specialty products, inhalation therapies, and APIs supplied to third parties. Several products compete in markets characterized by limited competition due to manufacturing complexity and regulatory barriers, which has historically supported pricing stability relative to more commoditized generic pharmaceuticals.

Strategic Position & Investments

Amphastar’s strategic direction has emphasized expansion into proprietary and specialty pharmaceutical products while maintaining its position in complex generics. The company has invested in respiratory therapies, diabetes rescue medications, and difficult-to-manufacture injectable products. A significant strategic initiative was the acquisition of BAQSIMI from Eli Lilly and Company, which added a commercially established glucagon nasal powder product to Amphastar’s portfolio and increased exposure to branded pharmaceutical markets. The company has also invested in expanding manufacturing capacity and research capabilities to support future abbreviated new drug applications (ANDAs) and proprietary pipeline development.

Amphastar has continued to pursue growth through product diversification, regulatory approvals, and lifecycle management strategies. Its investments in inhalation and intranasal delivery technologies reflect a broader focus on differentiated drug-device combinations and specialty therapeutics. The company’s vertically integrated API capabilities, particularly in insulin-related products, provide strategic control over portions of its supply chain and product economics. Public disclosures and industry reporting indicate continued emphasis on high-barrier generic markets and specialty pharmaceutical expansion rather than large-scale acquisition-driven growth.

Geographic Footprint

Amphastar is headquartered in Rancho Cucamonga, California, and maintains operational facilities across multiple regions. Its primary commercial market is the United States, where the majority of revenue is generated through pharmaceutical distribution channels serving hospitals, pharmacies, and healthcare providers. The company also operates manufacturing and development facilities in California, New York, China, and France, supporting both domestic production and international supply activities.

Internationally, Amphastar maintains a manufacturing and development presence through subsidiaries including Amphastar Nanjing Pharmaceuticals Inc. in China and operations in France associated with glucagon-related products. The company’s geographic footprint supports API production, finished dose manufacturing, and research activities. Although Amphastar’s direct commercial exposure outside the United States is smaller relative to multinational pharmaceutical peers, its international operations contribute to manufacturing integration, regulatory flexibility, and supply chain capabilities.

Leadership & Governance

Amphastar Pharmaceuticals was founded by members of the Wang family, who continue to play significant leadership roles within the organization. The company operates under a management structure combining scientific, operational, and pharmaceutical industry expertise. Leadership strategy has consistently emphasized vertically integrated manufacturing, development of technically complex pharmaceuticals, and long-term investment in specialty and generic product capabilities.

Key executives include:

• Dr. Jack Y. Zhang – Chairman of the Board, President, and Chief Executive Officer
• William J. Peters – Executive Vice President and Chief Financial Officer
• Dr. Gary K. Wang – Executive Vice President and Chief Scientific Officer
• Diane G. Gersten – General Counsel and Corporate Secretary
• Dr. James E. Fang – Senior Vice President of Regulatory Affairs

Company governance and operational strategy are guided through executive oversight, board supervision, and regulatory compliance frameworks reflected in public filings including SEC Form 10-K, quarterly filings, and investor disclosures. Leadership communications have consistently highlighted disciplined capital allocation, investment in complex product development, and expansion of proprietary pharmaceutical assets as central elements of Amphastar’s long-term strategy.